Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23921120 | 0.91 | ADORA3 (0.41) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL23921079 | 0.90 | ADORA3 (0.46) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL21396504 | 0.90 | ADORA3 (0.42) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL23921015 | 0.90 | ADORA3 (0.40) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL23921240 | 0.89 | ADORA3 (0.51) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL23921157 | 0.88 | TDP1 (0.41) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL23921154 | 0.87 | ADORA3 (0.49) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL23921239 | 0.87 | ADORA3 (0.38) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL23920872 | 0.87 | MEN1 (0.40) | ADORA1ADORA2BADORA2AADORA3TDP1 | |
| SCHEMBL21396379 | 0.85 | ADORA3 (0.40) | ADORA1ADORA2BADORA2AADORA3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20220402964-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANSINE-3', 5'-CYCLIC MONOPHOSPHATES | Graybug Vision, Inc. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | ADORA1 857/4885ADORA2B 1531/4885ADORA2A 597/4885 |
| US-20220402964-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PDE7A, PDE5A | ADORA1 764/4885ADORA2B 1538/4885ADORA2A 561/4885 |
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PDE7A, PRKG1, PDE4C | ADORA1 578/4885ADORA2B 925/4885ADORA2A 368/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | ADORA1 828/4885ADORA2B 1519/4885ADORA2A 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.